Adial Pharmaceuticals, Inc.
ADIL
$6.44
-$0.21-3.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 244.17% | 23.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 191.78% | 6.16% | |||
| Operating Income | -191.78% | -6.16% | |||
| Income Before Tax | -2,470.66% | -1.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2,470.66% | -1.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,470.66% | -1.31% | |||
| EBIT | -191.78% | -6.16% | |||
| EBITDA | -191.81% | -6.16% | |||
| EPS Basic | -662.06% | 19.10% | |||
| Normalized Basic EPS | 103.66% | 19.10% | |||
| EPS Diluted | -662.06% | 19.10% | |||
| Normalized Diluted EPS | 103.66% | 19.10% | |||
| Average Basic Shares Outstanding | 237.33% | 25.24% | |||
| Average Diluted Shares Outstanding | 237.33% | 25.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||